Merck
CN
  • Multicenter, double-blind, parallel group study investigating the non-inferiority of efficacy and safety of a 2% miconazole nitrate shampoo in comparison with a 2% ketoconazole shampoo in the treatment of seborrhoeic dermatitis of the scalp.

Multicenter, double-blind, parallel group study investigating the non-inferiority of efficacy and safety of a 2% miconazole nitrate shampoo in comparison with a 2% ketoconazole shampoo in the treatment of seborrhoeic dermatitis of the scalp.

The Journal of dermatological treatment (2013-04-06)
Stanislaw A Buechner
摘要

This study investigated the non-inferiority of efficacy and tolerance of 2% miconazole nitrate shampoo in comparison with 2% ketoconazole shampoo in the treatment of scalp seborrheic dermatitis. A randomized, double-blind, comparative, parallel group, multicenter study was done. A total of 274 patients (145 miconazole, 129 ketoconazole) were enrolled. Treatment was twice-weekly for 4 weeks. Safety and efficacy assessments were made at baseline and at weeks 2 and 4. Assessments included symptoms of erythema, itching, scaling ['Symptom Scale of Seborrhoeic Dermatitis' (SSSD)], disease severity and global change [Clinical Global Impressions (CGIs) and Patient Global Impressions (PGIs)]. Miconazole shampoo is at least as effective and safe as ketoconazole shampoo in treating scalp seborrheic dermatitis scalp.

材料
货号
品牌
产品描述

Supelco
酮康唑, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
(±)-咪康唑 硝酸盐, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
酮康唑, 99.0-101.0% (EP, titration)
Sigma-Aldrich
酮康唑
USP
酮康唑, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
(±)-咪康唑 硝酸盐, imidazole antibiotic
咪康唑, European Pharmacopoeia (EP) Reference Standard
酮康唑, European Pharmacopoeia (EP) Reference Standard
USP
(±)-咪康唑 硝酸盐, United States Pharmacopeia (USP) Reference Standard
咪康唑, European Pharmacopoeia (EP) Reference Standard